Atypical hemolytic uremic syndrome responsive to steroids and intravenous immune globulin

Tanya Watt, Barry Warshaw, Howard M. Katzenstein

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Atypical hemolytic uremic syndrome remains a challenge to diagnose and treat, with significant acute morbidity and risk for progression to end stage renal disease. Treatment strategies center on plasma exchange but do not necessarily affect the progression of disease. We report the case of a patient with atypical HUS resulting from a mutation in the complement pathway who responded to treatment with steroids and IVIG, therefore avoiding transfusion or plasma exchange.

Original languageEnglish (US)
Pages (from-to)90-91
Number of pages2
JournalPediatric Blood and Cancer
Volume53
Issue number1
DOIs
StatePublished - Jul 15 2009

Fingerprint

Plasma Exchange
Intravenous Immunoglobulins
Steroids
Chronic Kidney Failure
Disease Progression
Morbidity
Mutation
Therapeutics
Atypical Hemolytic Uremic Syndrome

Keywords

  • Anemia
  • Hemolytic
  • Steroids
  • Uremic

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Medicine(all)

Cite this

Atypical hemolytic uremic syndrome responsive to steroids and intravenous immune globulin. / Watt, Tanya; Warshaw, Barry; Katzenstein, Howard M.

In: Pediatric Blood and Cancer, Vol. 53, No. 1, 15.07.2009, p. 90-91.

Research output: Contribution to journalArticle

Watt, Tanya ; Warshaw, Barry ; Katzenstein, Howard M. / Atypical hemolytic uremic syndrome responsive to steroids and intravenous immune globulin. In: Pediatric Blood and Cancer. 2009 ; Vol. 53, No. 1. pp. 90-91.
@article{2c0e95b34dc24b1480466e7ab5939ba0,
title = "Atypical hemolytic uremic syndrome responsive to steroids and intravenous immune globulin",
abstract = "Atypical hemolytic uremic syndrome remains a challenge to diagnose and treat, with significant acute morbidity and risk for progression to end stage renal disease. Treatment strategies center on plasma exchange but do not necessarily affect the progression of disease. We report the case of a patient with atypical HUS resulting from a mutation in the complement pathway who responded to treatment with steroids and IVIG, therefore avoiding transfusion or plasma exchange.",
keywords = "Anemia, Hemolytic, Steroids, Uremic",
author = "Tanya Watt and Barry Warshaw and Katzenstein, {Howard M.}",
year = "2009",
month = "7",
day = "15",
doi = "10.1002/pbc.21951",
language = "English (US)",
volume = "53",
pages = "90--91",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Atypical hemolytic uremic syndrome responsive to steroids and intravenous immune globulin

AU - Watt, Tanya

AU - Warshaw, Barry

AU - Katzenstein, Howard M.

PY - 2009/7/15

Y1 - 2009/7/15

N2 - Atypical hemolytic uremic syndrome remains a challenge to diagnose and treat, with significant acute morbidity and risk for progression to end stage renal disease. Treatment strategies center on plasma exchange but do not necessarily affect the progression of disease. We report the case of a patient with atypical HUS resulting from a mutation in the complement pathway who responded to treatment with steroids and IVIG, therefore avoiding transfusion or plasma exchange.

AB - Atypical hemolytic uremic syndrome remains a challenge to diagnose and treat, with significant acute morbidity and risk for progression to end stage renal disease. Treatment strategies center on plasma exchange but do not necessarily affect the progression of disease. We report the case of a patient with atypical HUS resulting from a mutation in the complement pathway who responded to treatment with steroids and IVIG, therefore avoiding transfusion or plasma exchange.

KW - Anemia

KW - Hemolytic

KW - Steroids

KW - Uremic

UR - http://www.scopus.com/inward/record.url?scp=66149093078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66149093078&partnerID=8YFLogxK

U2 - 10.1002/pbc.21951

DO - 10.1002/pbc.21951

M3 - Article

C2 - 19301397

AN - SCOPUS:66149093078

VL - 53

SP - 90

EP - 91

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 1

ER -